Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
Read More
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…
Hamlet Pharma is proud to announce the successful outcome of the Phase I/II trial, aimed at studying the safety and efficacy of Alpha1H in patients…
The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…
Dose-escalation studies have been performed to find the optimal dose of Alpha1H for future therapeutic studies. In the murine bladder cancer model, we observed a…
The Board of Hamlet Pharma AB has decided on a new date for the Annual General Meeting. The new date of the Annual General Meeting is Thursday,…
With Hamlet,from breast milk and the “foundation of life”to cancer therapy that improves the quality of life World Breastfeeding Week 2018 begins today, a worldwide,…
HAMLET Pharma has formally appointed Prof Catharina Svanborg, Chairman and founder of HAMLET Pharma, as Chief Medical Officer (CMO), to enable her to continue her…
HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims…